Cloud-clone
SKU:MAD559Hu21
Monoclonal Antibody to Mitogen Activated Protein Kinase Kinase 1 (MAP2K1)
Monoclonal Antibody to Mitogen Activated Protein Kinase Kinase 1 (MAP2K1)
Couldn't load pickup availability
Western blotting: 0.2-2µg/mL;1:500-5000
Immunohistochemistry: 5-20µg/mL;1:50-200
Immunocytochemistry: 5-20µg/mL;1:50-200
Optimal working dilutions must be determined by end user.
Product No.
MAD559Hu21
Organism Species
Homo sapiens (Human).
Source
Monoclonal antibody preparation
Host
Mouse
Potency (Clone Number)
n/a
Ig Isotype
IgG
Purification
Antigen-specific affinity chromatography followed by Protein A affinity chromatography
Label
None
Immunogen
n/a
Buffer Formulation
PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Traits
Liquid
Concentration
1mg/mL
Organism Species More
n/a
Applications
WB; IHC; ICC; IP.
If the antibody is used in flow cytometry, please check FCM antibodies.
UOM
20µl 100µl 200µl 1ml 10ml
SPECIFITY
The antibody is a mouse monoclonal antibody raised against MAP2K1. It has been selected for its ability to recognize MAP2K1 in immunohistochemical staining and western blotting.
USAGE
Western blotting: 0.2-2µg/mL;1:500-5000
Immunohistochemistry: 5-20µg/mL;1:50-200
Immunocytochemistry: 5-20µg/mL;1:50-200
Optimal working dilutions must be determined by end user.
STORAGE
Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for two year without detectable loss of activity. Avoid repeated freeze-thaw cycles.
STABILITY
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
| Magazine | Citations |
| Graefe's Archive for Clinical and Experimental Ophthalmology | Role of RhoA/MERK1/ERK1/2/iNOS signaling in ocular ischemic syndrome pubmed:27538909 |
| PLOS ONE | Identification of Biomarkers of Impaired Sensory Profiles among Autistic Patients. pubmed:27824861 |
| Cancers | Rationale for a Combination Therapy Consisting of MCL1-and MEK-Inhibitors in Acute Myeloid Leukemia Pubmed: 31718075 |
| Cancers (Basel) | BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia. Cancers 2021, 13, 581 33540760 |
| Catalog No. | Related products for research use of Homo sapiens (Human) Organism species | Applications (RESEARCH USE ONLY!) |
| RPD559Hu01 | Recombinant Mitogen Activated Protein Kinase Kinase 1 (MAP2K1) | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAD559Hu01 | Polyclonal Antibody to Mitogen Activated Protein Kinase Kinase 1 (MAP2K1) | WB; IHC; ICC; IP. |
| MAD559Hu21 | Monoclonal Antibody to Mitogen Activated Protein Kinase Kinase 1 (MAP2K1) | WB; IHC; ICC; IP. |
| SED559Hu | ELISA Kit for Mitogen Activated Protein Kinase Kinase 1 (MAP2K1) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMD559Hu | Magnetic Luminex Assay Kit for Mitogen Activated Protein Kinase Kinase 1 (MAP2K1) ,etc. | Magnetic Luminex Assay for Antigen Detection. |
Share
